Switching to Faricimab May Extend Dosing Intervals in nAMD
Patients with treatment-resistant neovascular age-related macular degeneration who switched from aflibercept to faricimab may experience longer dosing intervals and better fluid control over three years, according to the report.
Why it matters
This may affect treatment strategies for patients with nAMD, though the evidence is observational.
Study duration
The findings were observed over a three-year period.
Common questions
What is nAMD?
nAMD stands for neovascular age-related macular degeneration, a condition that affects vision.
What was the main finding?
Switching from aflibercept to faricimab was linked to longer dosing intervals and better fluid control over three years.
Sources
- Switch to Faricimab May Extend Dosing Intervals in nAMD Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
